{"disease":{"id":"treatment-na-ve","name":"treatment na ve"},"drugs":{"marketed":[{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed oxaliplatin-based chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."}],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (treatment-naïve and treatment-experienced)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":47,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07429929","title":"Saudi Emergency Laparotomy Audit","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT07474142","title":"A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT07531329","title":"Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT06890026","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":742,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03856411","title":"A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":465,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05040126","title":"Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Tuberculosis Research Centre, India","has_results":false},{"nct_id":"NCT04155515","title":"A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT02203773","title":"Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":212,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT06510764","title":"A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT04961710","title":"Extension Study of Hetrombopag in Severe Aplastic Anemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03593447","title":"To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT02825836","title":"Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT03991572","title":"rTMS Intervention on Motivational Anhedonia of Treatment Resistant Depression and Brian Network Mechanism","phase":"NA","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT07210177","title":"The Success of Root Canal Treatments Performed Using Two Different Intracanal Medicaments","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT06550687","title":"Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Centre Georges Francois Leclerc","has_results":false},{"nct_id":"NCT07027722","title":"Clinical Practices for Treating Severe Malaria Caused by P. Falciparum","phase":"","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Centre Hospitalier de Saint-Denis","has_results":false},{"nct_id":"NCT05355142","title":"An Intervention Study of Anhedonia and Pain Empathy in Depression","phase":"NA","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT04309045","title":"Assessment of Cost-effectiveness in Two Empirically-based Psychotherapies for Borderline Personality Disorder: A Randomized Controlled Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Shalvata Mental Health Center","has_results":false},{"nct_id":"NCT03563599","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Qurient Co., Ltd.","has_results":false},{"nct_id":"NCT02213913","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT06042218","title":"Xiaxi Program for Back Health","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Universidad Católica San Antonio de Murcia","has_results":false},{"nct_id":"NCT02141659","title":"A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06554535","title":"Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT04548700","title":"Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07104149","title":"Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT05262985","title":"Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":22,"lead_sponsor_name":"Elizabeth Dudnik","has_results":false},{"nct_id":"NCT01805037","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT07126678","title":"Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05615948","title":"Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Maimonides Medical Center","has_results":false},{"nct_id":"NCT04925986","title":"Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Sarah Goldberg","has_results":true},{"nct_id":"NCT05051891","title":"A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}